DC-34

DC-34 is a selective stabilizer of MYC G-quadruplexes (G4s), with measured K_d values of 9.4 μM (FIA), 1.4 μM (SPR), and 16.5 μM (NMR) across different assays. DC-34 downregulates MYC levels in cancer cells in a G4-dependent manner, reduces cell viability, and induces G0-G1 cell cycle arrest and p16-marked senescence in MYC-driven multiple myeloma cells. DC-34 can serve as a probe for G4-dependent gene regulation studies and is applicable to research on multiple myeloma^[1]. In Vitro:DC-34 (up to 100 μM; 24-72 h) inhibits L363 multiple myeloma cell viability with IC₅₀ values of 3.4 μM (24 h), 3.4 μM (48 h), and 3.1 μM (72 h)^[1].
DC-34 (0.1-10 μM; 4-72 h) potently and selectively reduces MYC protein levels in L363 multiple myeloma cells (IC₅₀ = 1.9 μM at 24 h) by a MYC G-quadruplex-dependent mechanism, with no effect in cells lacking the MYC G-quadruplex promoter sequence^[1].
DC₃₄ (2.5-7.5 μM; 24-48 h) potently downregulates MYC transcription in L363 multiple myeloma cells in vitro in a time- and dose-dependent manner, with minimal effects on other tested G4-driven oncogenes^[1].
DC₃₄ (5 μM; up to 75 min) does not affect MYC protein stability in L363 multiple myeloma cells, indicating its inhibitory effect on MYC occurs at the transcriptional level^[1].
DC₅₀-34 (5 μM; 48 h) induces G0/G1 cell cycle arrest (63.54% of cells) and senescence marker p16 expression in L363 multiple myeloma cells after 48 h of treatment^[1].